Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system.
Explore this paper's citation graph
Summary
In younger patients with AML, the ELN classification seems to be the best available framework for prognostic estimations to date, and caution is advised concerning its use for prospective treatment allocation before it has been prospectively validated.
- Type
- article
- Published
- 2011-07-10
- Cited by
- 258
- References
- 31
- Access
- Open access
- OpenAlex
- https://openalex.org/W2100883771
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:25658890
Keywords
Medicine, Internal medicine, Myeloid leukemia, Cohort, Adverse effect
References
- Multivariate analyses of prognostic factors in acute myeloid leukemia: relevance of cytogenetic abnormalities and CD34 expression.
- Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.
- The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.
- Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).
- A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.
- Risk Assessment in Patients with Acute Myeloid Leukemia and a Normal Karyotype
- Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
- Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials
- Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B.
- Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia.
- Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.
- Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
- Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML.
- A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial.
- Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.
- New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients.
- Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.
- Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.
- CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.
- Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.
Cited by
- Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia
- Acute Myelogenous Leukemia at Baylor Charles A. Sammons Cancer Center, 2010 to 2012: Retrospective Analysis of Molecular Genetic Evaluation
- Studies on CEBPA mutations in acute myeloid leukaemia
- Acute Myeloid Leukemia With Adverse Cytogenetic Risk
- A study of chemotherapy resistance in acute myeloid leukemia
- Secondary Adult Acute Myeloid Leukemia: a Review of Our Evolving Understanding of a Complex Disease Process
- Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus.
- Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse
- Akute myeloische Leukämie
- FLAMSA reduced‐intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission
- Complex molecular genetic abnormalities involving three or more genetic mutations are important prognostic factors for acute myeloid leukemia
- Clinical outcomes of patients with acute myeloid leukemia: evaluation of genetic and molecular findings in a real-life setting.
- Management of Newly Diagnosed Acute Myeloid Leukemia in the Elderly: Current Strategies and Future Directions
- Acute Myeloid Leukemia Genetics: Risk Stratification and Implications for Therapy.
- Is it time to change conventional consolidation chemotherapy for acute myeloid leukemia in CR1?
- Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine.
- Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML
- Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia: To Whom, When, and How
- Next generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma
- Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia.
Related papers
- [Advances in the mouse models of myeloid leukemia].
- Expression of sICAM-1 in Patients with Hyperleukocytic Acute Leukemia and Its Clinical Significance
- 非定型的白血病（Hypoplastic Leukemia or Smoldering Acute Leukemia）に関する研究 第2編 骨髄における白血病細胞の大きさ，(3)H-Thymidineによるin vitro標識率ならびに臨床骨髄培養所見の検討
- Relationship between the expression of MMP-2 and MMP-9 in acute leukemia cells and leukemia infiltration
- EFFECTS OF LONG-TERM COMBINED CHEMOTHERAPY ON SISTER CHROMATID EXCHANGE IN THE PATIENTS WITH ADULT LEUKEMIA
- Studies on the Atypical Leukemia (Hypoplastic or Smoldering Acute Leukemia): Part II. On the Cell Size and Laveling Index with 3 H-thymidine of Leukemic Blasts and Pattern of Bone Marrow Tissue Culture of Atypical Leukemia@@@第2編 骨髄における白血病細胞の大きさ, 3 H-Thymidineによるin vitro標識率ならびに臨床骨髄培養所見の検討